Advertisement

HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient

  • Jennifer E. Cameron
  • Michael Hagensee
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 177)

Abstract

Since their discovery as the etiologic agents of cervical cancer in the mid-1970s, human papillomaviruses (HPVs) have been linked with a growing number of epithelial-derived tumors, including head and neck squamous cell carcinomas. HPV demonstrates a particular predilection for causing tumors of the oropharynx, with the majority of cases involving infection with high-oncogenic risk HPV-16. People living with HIV are at increased risk of infection with HPV- and HPV-related oral complications even with adequate control of their HIV infection with antiretroviral therapy. In this chapter, we discuss the molecular mechanisms that underlie HPV-mediated oncogenesis in the oropharynx. We also describe the progress that has been made in understanding the epidemiology of oral HPV infection and the determinants of oral HPV-related pathology. Finally, we examine what can be done to treat and prevent oral HPV infection, benign lesions, and cancer, particularly in the context of the HIV-positive patient.

References

  1. 1.
    Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136CrossRefGoogle Scholar
  2. 2.
    Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Can Res 56:4620–4624Google Scholar
  3. 3.
    Gonzalez SL, Stremlau M, He X, Basile JR, Munger K (2001) Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 75:7583–7591CrossRefGoogle Scholar
  4. 4.
    Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, Nevins JR (1992) Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89:4549–4553CrossRefGoogle Scholar
  5. 5.
    Johnson DG, Schwarz JK, Cress WD, Nevins JR (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349–352CrossRefGoogle Scholar
  6. 6.
    Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J (1983) Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 12:418–424CrossRefGoogle Scholar
  7. 7.
    El-Mofty SK, Lu DW (2003) Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol 27:1463–1470CrossRefGoogle Scholar
  8. 8.
    Fouret P, Monceaux G, Temam S, Lacourreye L, St Guily JL (1997) Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers. Arch Otolaryngol Head Neck Surg 123:513–516CrossRefGoogle Scholar
  9. 9.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720CrossRefGoogle Scholar
  10. 10.
    Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR (1996) Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 2:755–762Google Scholar
  11. 11.
    Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister HJ, Fuchs PG (2001) Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92:2875–2884CrossRefGoogle Scholar
  12. 12.
    Niedobitek G, Pitteroff S, Herbst H, Shepherd P, Finn T, Anagnostopoulos I, Stein H (1990) Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol 43:918–921CrossRefGoogle Scholar
  13. 13.
    Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP (1997) Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer’s tonsillar ring. Cancer 79:595–604CrossRefGoogle Scholar
  14. 14.
    Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT (2002) Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8:3187–3192Google Scholar
  15. 15.
    Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336–344CrossRefGoogle Scholar
  16. 16.
    Perry ME (1994) The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat 185(Pt 1):111–127PubMedCentralGoogle Scholar
  17. 17.
    Brandsma JL, Abramson AL (1989) Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 115:621–625CrossRefGoogle Scholar
  18. 18.
    Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Mao EJ, Fitzgibbons ED, Huang S, Beckmann AM, McDougall JK, Galloway DA (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626–1636CrossRefGoogle Scholar
  19. 19.
    Snijders PJ, Cromme FV, van den Brule AJ, Schrijnemakers HF, Snow GB, Meijer CJ, Walboomers JM (1992) Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int J Cancer 51:845–850CrossRefGoogle Scholar
  20. 20.
    Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC, McGovern R, Weaver AL, Persing D, Kasperbauer JL (2002) Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 8:1093–1100 (An official journal of the American Association for Cancer Research)Google Scholar
  21. 21.
    Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Can Res 63:1188–1191Google Scholar
  22. 22.
    Begum S, Cao D, Gillison M, Zahurak M, Westra WH (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694–5699 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  23. 23.
    Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, Eckel HE, Pfister HJ, Fuchs PG (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747–753CrossRefGoogle Scholar
  24. 24.
    Koskinen WJ, Chen RW, Leivo I, Makitie A, Back L, Kontio R, Suuronen R, Lindqvist C, Auvinen E, Molijn A, Quint WG, Vaheri A, Aaltonen LM (2003) Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107:401–406CrossRefGoogle Scholar
  25. 25.
    van Houten VM, Snijders PJ, van den Brekel MW, Kummer JA, Meijer CJ, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH (2001) Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 93:232–235CrossRefGoogle Scholar
  26. 26.
    Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p 53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517CrossRefGoogle Scholar
  27. 27.
    Wilczynski SP, Lin BT, Xie Y, Paz IB (1998) Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 152:145–156PubMedCentralGoogle Scholar
  28. 28.
    Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Can Res 58:5–13Google Scholar
  29. 29.
    Brachman DG, Graves D, Vokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D, Weichselbaum RR (1992) Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Can Res 52:4832–4836Google Scholar
  30. 30.
    Hafkamp HC, Speel EJ, Haesevoets A, Bot FJ, Dinjens WN, Ramaekers FC, Hopman AH, Manni JJ (2003) A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 107:394–400CrossRefGoogle Scholar
  31. 31.
    Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR (2002) Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 24:841–849CrossRefGoogle Scholar
  32. 32.
    Snijders PJ, Steenbergen RD, Top B, Scott SD, Meijer CJ, Walboomers JM (1994) Analysis of p53 status in tonsillar carcinomas associated with human papillomavirus. J Gen Virol 75(Pt 10):2769–2775CrossRefGoogle Scholar
  33. 33.
    Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Can Res 54:6078–6082Google Scholar
  34. 34.
    Ohtani N, Yamakoshi K, Takahashi A, Hara E (2004) The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest 51:146–153CrossRefGoogle Scholar
  35. 35.
    Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG (1997) Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 14:811–818CrossRefGoogle Scholar
  36. 36.
    Shintani S, Nakahara Y, Mihara M, Ueyama Y, Matsumura T (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 37:498–504CrossRefGoogle Scholar
  37. 37.
    Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475 (An official journal of the American Association for Cancer Research)Google Scholar
  38. 38.
    Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, Clavero O, Alos L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimera N, Lloveras B, Leon X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Felix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, Lopez-Revilla R, Mandys V, Gonzalez ME, Velasco J, Bravo IG, Quint W, Pawlita M, Munoz N, de Sanjose S, Xavier Bosch F (2016) HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403CrossRefGoogle Scholar
  39. 39.
    Dok R, Kalev P, Van Limbergen EJ, Asbagh LA, Vazquez I, Hauben E, Sablina A, Nuyts S (2014) p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Can Res 74:1739–1751CrossRefGoogle Scholar
  40. 40.
    Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474:230–234CrossRefGoogle Scholar
  41. 41.
    Sakakibara N, Mitra R, McBride AA (2011) The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol 85:8981–8995CrossRefGoogle Scholar
  42. 42.
    McBride AA, Warburton A (2017) The role of integration in oncogenic progression of HPV-associated cancers. PLoS Pathog 13:e1006211CrossRefGoogle Scholar
  43. 43.
    Dooley KE, Warburton A, McBride AA (2016) Tandemly integrated HPV16 can form a Brd4-dependent super-enhancer-like element that drives transcription of viral oncogenes. MBio 7Google Scholar
  44. 44.
    Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R (2014) Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci USA 111:15544–15549CrossRefGoogle Scholar
  45. 45.
    Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML (2014) Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24:185–199CrossRefGoogle Scholar
  46. 46.
    Walline HM, Carey TE, Goudsmit CM, Bellile EL, D’Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL (2017) High-risk HPV, biomarkers, and outcome in matched cohorts of head and neck cancer patients positive and negative for HIV. Mol Cancer Res MCR 15:179–188CrossRefGoogle Scholar
  47. 47.
    Olthof NC, Speel EJ, Kolligs J, Haesevoets A, Henfling M, Ramaekers FC, Preuss SF, Drebber U, Wieland U, Silling S, Lam WL, Vucic EA, Kremer B, Klussmann JP, Huebbers CU (2014) Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS ONE 9:e88718CrossRefGoogle Scholar
  48. 48.
    Walline HM, Goudsmit CM, McHugh JB, Tang AL, Owen JH, Teh BT, McKean E, Glover TW, Graham MP, Prince ME, Chepeha DB, Chinn SB, Ferris RL, Gollin SM, Hoffmann TK, Bier H, Brakenhoff R, Bradford CR, Carey TE, University of Michigan H, Neck Specialized Program of Research Excellence P (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840–852CrossRefGoogle Scholar
  49. 49.
    Hu Z, Zhu D, Wang W, Li W, Jia W, Zeng X, Ding W, Yu L, Wang X, Wang L, Shen H, Zhang C, Liu H, Liu X, Zhao Y, Fang X, Li S, Chen W, Tang T, Fu A, Wang Z, Chen G, Gao Q, Li S, Xi L, Wang C, Liao S, Ma X, Wu P, Li K, Wang S, Zhou J, Wang J, Xu X, Wang H, Ma D (2015) Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 47:158–163CrossRefGoogle Scholar
  50. 50.
    Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582CrossRefGoogle Scholar
  51. 51.
    Wentzensen N, Vinokurova S, von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Can Res 64:3878–3884CrossRefGoogle Scholar
  52. 52.
    Bodelon C, Vinokurova S, Sampson JN, den Boon JA, Walker JL, Horswill MA, Korthauer K, Schiffman M, Sherman ME, Zuna RE, Mitchell J, Zhang X, Boland JF, Chaturvedi AK, Dunn ST, Newton MA, Ahlquist P, Wang SS, Wentzensen N (2016) Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis 37:188–196CrossRefGoogle Scholar
  53. 53.
    Safe S, Jin UH, Hedrick E, Reeder A, Lee SO (2014) Minireview: role of orphan nuclear receptors in cancer and potential as drug targets. Mol Endocrinol 28:157–172CrossRefGoogle Scholar
  54. 54.
    Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK (2004) Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10:3825–3830 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  55. 55.
    Lleras RA, Smith RV, Adrien LR, Schlecht NF, Burk RD, Harris TM, Childs G, Prystowsky MB, Belbin TJ (2013) Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res 19:5444–5455 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  56. 56.
    Sartor MA, Dolinoy DC, Jones TR, Colacino JA, Prince ME, Carey TE, Rozek LS (2011) Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 6:777–787CrossRefGoogle Scholar
  57. 57.
    Schlecht NF, Ben-Dayan M, Anayannis N, Lleras RA, Thomas C, Wang Y, Smith RV, Burk RD, Harris TM, Childs G, Ow TJ, Prystowsky MB, Belbin TJ (2015) Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma. Cancer Med 4:342–353CrossRefGoogle Scholar
  58. 58.
    Laurson J, Khan S, Chung R, Cross K, Raj K (2010) Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31:918–926CrossRefGoogle Scholar
  59. 59.
    Anayannis NV, Schlecht NF, Belbin TJ (2015) Epigenetic mechanisms of human papillomavirus-associated head and neck cancer. Arch Pathol Lab Med 139:1373–1378CrossRefGoogle Scholar
  60. 60.
    Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K (2003) Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways. Nucleic Acids Res 31:3101–3113CrossRefGoogle Scholar
  61. 61.
    Koutsodontis G, Tentes I, Papakosta P, Moustakas A, Kardassis D (2001) Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J Biol Chem 276:29116–29125CrossRefGoogle Scholar
  62. 62.
    Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F (2007) Viral oncoproteins target the DNA methyltransferases. Oncogene 26:1650–1655CrossRefGoogle Scholar
  63. 63.
    Sawada M, Kanai Y, Arai E, Ushijima S, Ojima H, Hirohashi S (2007) Increased expression of DNA methyltransferase 1 (DNMT1) protein in uterine cervix squamous cell carcinoma and its precursor lesion. Cancer Lett 251:211–219CrossRefGoogle Scholar
  64. 64.
    van Kempen PM, Noorlag R, Braunius WW, Stegeman I, Willems SM, Grolman W (2014) Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 9:194–203CrossRefGoogle Scholar
  65. 65.
    Wilson GA, Lechner M, Koferle A, Caren H, Butcher LM, Feber A, Fenton T, Jay A, Boshoff C, Beck S (2013) Integrated virus-host methylome analysis in head and neck squamous cell carcinoma. Epigenetics 8:953–961CrossRefGoogle Scholar
  66. 66.
    Weiss D, Basel T, Sachse F, Braeuninger A, Rudack C (2011) Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation. Mol Carcinog 50:680–688CrossRefGoogle Scholar
  67. 67.
    van Kempen PM, van Bockel L, Braunius WW, Moelans CB, van Olst M, de Jong R, Stegeman I, van Diest PJ, Grolman W, Willems SM (2014) HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med 3:1185–1196CrossRefGoogle Scholar
  68. 68.
    Chen KM, Stephen JK, Havard S, Mahan M, Divine G, Worsham MJ (2015) IGSF4 methylation as an independent marker of human papillomavirus-positive oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 141:257–263CrossRefGoogle Scholar
  69. 69.
    Marsit CJ, McClean MD, Furniss CS, Kelsey KT (2006) Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 119:1761–1766CrossRefGoogle Scholar
  70. 70.
    Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Hofler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J (2013) HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Investig 123:2488–2501CrossRefGoogle Scholar
  71. 71.
    Miller DL, Puricelli MD, Stack MS (2012) Virology and molecular pathogenesis of HPV (human papillomavirus)-associated oropharyngeal squamous cell carcinoma. Biochem J 443:339–353CrossRefGoogle Scholar
  72. 72.
    Patel D, Huang SM, Baglia LA, McCance DJ (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18:5061–5072CrossRefGoogle Scholar
  73. 73.
    Veldman T, Liu X, Yuan H, Schlegel R (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA 100:8211–8216CrossRefGoogle Scholar
  74. 74.
    Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, Teknos TN, Arora PS, Pan Q (2014) Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 33:1037–1046CrossRefGoogle Scholar
  75. 75.
    Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11:726–734CrossRefGoogle Scholar
  76. 76.
    Bodily JM, Mehta KP, Laimins LA (2011) Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases. Can Res 71:1187–1195CrossRefGoogle Scholar
  77. 77.
    McLaughlin-Drubin ME, Crum CP, Munger K (2011) Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 108:2130–2135CrossRefGoogle Scholar
  78. 78.
    Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, Peters G, Gil J (2009) Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23:1177–1182CrossRefGoogle Scholar
  79. 79.
    Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Durst M, Hoppe-Seyler F (2008) Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Can Res 68:9964–9972CrossRefGoogle Scholar
  80. 80.
    Biron VL, Mohamed A, Hendzel MJ, Alan Underhill D, Seikaly H (2012) Epigenetic differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. J Otolaryngol—Head Neck Surg = Le Journal d’oto-rhino-laryngologie et de chirurgie cervico-faciale 41(1):S65–S70Google Scholar
  81. 81.
    Brieger J, Mann SA, Pongsapich W, Koutsimpelas D, Fruth K, Mann WJ (2012) Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med 29:505–509Google Scholar
  82. 82.
    Chung YL, Lee MY, Pui NN (2009) Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30:1387–1397CrossRefGoogle Scholar
  83. 83.
    Diyabalanage HV, Granda ML, Hooker JM (2013) Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 329:1–8CrossRefGoogle Scholar
  84. 84.
    Gasche JA, Goel A (2012) Epigenetic mechanisms in oral carcinogenesis. Future Oncol 8:1407–1425CrossRefGoogle Scholar
  85. 85.
    Viet CT, Dang D, Achdjian S, Ye Y, Katz SG, Schmidt BL (2014) Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. PLoS ONE 9:e112880CrossRefGoogle Scholar
  86. 86.
    Lajer CB, Garnaes E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, Rossing M, Lajer H, Svane D, Skotte L, Specht L, Buchwald C, Nielsen FC (2012) The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 106:1526–1534CrossRefGoogle Scholar
  87. 87.
    Miller DL, Davis JW, Taylor KH, Johnson J, Shi Z, Williams R, Atasoy U, Lewis JS Jr, Stack MS (2015) Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas. Am J Pathol 185:679–692CrossRefGoogle Scholar
  88. 88.
    Zheng ZM, Wang X (2011) Regulation of cellular miRNA expression by human papillomaviruses. Biochem Biophys Acta 1809:668–677Google Scholar
  89. 89.
    Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL, Lewis JS Jr, Wang X (2013) A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer 119:72–80CrossRefGoogle Scholar
  90. 90.
    Hui AB, Lin A, Xu W, Waldron L, Perez-Ordonez B, Weinreb I, Shi W, Bruce J, Huang SH, O’Sullivan B, Waldron J, Gullane P, Irish JC, Chan K, Liu FF (2013) Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 19:2154–2162 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  91. 91.
    Lajer CB, Nielsen FC, Friis-Hansen L, Norrild B, Borup R, Garnaes E, Rossing M, Specht L, Therkildsen MH, Nauntofte B, Dabelsteen S, von Buchwald C (2011) Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study. Br J Cancer 104:830–840CrossRefGoogle Scholar
  92. 92.
    Manasa VG, Kannan S (2017) Impact of microRNA dynamics on cancer hallmarks: an oral cancer scenario. Tumour Biol 39:1010428317695920CrossRefGoogle Scholar
  93. 93.
    Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, Shi W, Perez-Ordonez B, Jurisica I, O’Sullivan B, Waldron J, Gullane P, Cummings B, Liu FF (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16:1129–1139 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  94. 94.
    Zhang X, Gee H, Rose B, Lee CS, Clark J, Elliott M, Gamble JR, Cairns MJ, Harris A, Khoury S, Tran N (2016) Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. BMC Cancer 16:86CrossRefGoogle Scholar
  95. 95.
    Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA (2011) Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 33:504–512CrossRefGoogle Scholar
  96. 96.
    Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA (2015) MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer 15:861CrossRefGoogle Scholar
  97. 97.
    Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ, Schlecht NF (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174:736–745CrossRefGoogle Scholar
  98. 98.
    Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, Prystowsky MB, Schlecht NF, Segall JE, Childs G (2012) Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 180:917–928CrossRefGoogle Scholar
  99. 99.
    Avissar M, McClean MD, Kelsey KT, Marsit CJ (2009) MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 30:2059–2063CrossRefGoogle Scholar
  100. 100.
    Chen X, Sturgis EM, Wang C, Cao X, Li Y, Wei Q, Li G (2016) Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. Oncotarget 7:35015–35025PubMedCentralGoogle Scholar
  101. 101.
    Firmino N, Martinez VD, Rowbotham DA, Enfield KSS, Bennewith KL, Lam WL (2016) HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer. Oral Oncol 55:43–48CrossRefGoogle Scholar
  102. 102.
    Wong N, Khwaja SS, Baker CM, Gay HA, Thorstad WL, Daly MD, Lewis JS Jr, Wang X (2016) Prognostic microRNA signatures derived from the cancer genome atlas for head and neck squamous cell carcinomas. Cancer Med 5:1619–1628CrossRefGoogle Scholar
  103. 103.
    Liu S, Song L, Yao H, Zhang L, Xu D, Gao F, Li Q (2016) MiR-375 is epigenetically downregulated by HPV-16 E6 mediated DNMT1 upregulation and modulates EMT of cervical cancer cells by suppressing lncRNA MALAT1. PLoS ONE 11:e0163460CrossRefGoogle Scholar
  104. 104.
    Jung HM, Phillips BL, Chan EK (2014) miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3zeta. Mol Cancer 13:80CrossRefGoogle Scholar
  105. 105.
    Jeffers LK, Duan K, Ellies LG, Seaman WT, Burger-Calderon RA, Diatchenko LB, Webster-Cyriaque J (2013) Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p 53 in small DNA tumor virus models. J Cancer Ther 4(3)Google Scholar
  106. 106.
    Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie P, Zhou G, Li G (2014) The role of MALAT1 correlates with HPV in cervical cancer. Oncol Lett 7:2135–2141CrossRefGoogle Scholar
  107. 107.
    Jimenez L, Jayakar SK, Ow TJ, Segall JE (2015) Mechanisms of invasion in head and neck cancer. Arch Pathol Lab Med 139:1334–1348CrossRefGoogle Scholar
  108. 108.
    Galvan SC, Martinez-Salazar M, Galvan VM, Mendez R, Diaz-Contreras GT, Alvarado-Hermida M, Alcantara-Silva R, Garcia-Carranca A (2011) Analysis of CpG methylation sites and CGI among human papillomavirus DNA genomes. BMC Genom 12:580CrossRefGoogle Scholar
  109. 109.
    Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, Sawakuma K, Takada K, Oikawa R, Watanabe Y, Yamamoto H, Itoh F, Myers JN, Oridate N (2017) Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer 140:1571–1580CrossRefGoogle Scholar
  110. 110.
    Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M (2009) The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19:438–451CrossRefGoogle Scholar
  111. 111.
    Mirabello L, Frimer M, Harari A, McAndrew T, Smith B, Chen Z, Wentzensen N, Wacholder S, Castle PE, Raine-Bennett T, Schiffman M, Burk RD (2015) HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer 136:E146–E153CrossRefGoogle Scholar
  112. 112.
    Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS, Chae YK, Lyford-Pike S, Westra WH, Saunders JR, Sidransky D, Pai SI (2011) Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res (Phila) 4:207–217CrossRefGoogle Scholar
  113. 113.
    Zhang C, Deng Z, Pan X, Uehara T, Suzuki M, Xie M (2015) Effects of methylation status of CpG sites within the HPV16 long control region on HPV16-Positive head and neck cancer cells. PLoS ONE 10:e0141245CrossRefGoogle Scholar
  114. 114.
    Reuschenbach M, Huebbers CU, Prigge ES, Bermejo JL, Kalteis MS, Preuss SF, Seuthe IM, Kolligs J, Speel EJ, Olthof N, Kremer B, Wagner S, Klussmann JP, Vinokurova S, von Knebel Doeberitz M (2015) Methylation status of HPV16 E2-binding sites classifies subtypes of HPV-associated oropharyngeal cancers. Cancer 121:1966–1976CrossRefGoogle Scholar
  115. 115.
    Harris RS, Dudley JP (2015) APOBECs and virus restriction. Virology 479–480:131–145CrossRefGoogle Scholar
  116. 116.
    Rebhandl S, Huemer M, Greil R, Geisberger R (2015) AID/APOBEC deaminases and cancer. Oncoscience 2:320–333CrossRefGoogle Scholar
  117. 117.
    Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D (2015) APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89:688–702CrossRefGoogle Scholar
  118. 118.
    Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM, Harris RS (2014) Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 5Google Scholar
  119. 119.
    Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833–1841CrossRefGoogle Scholar
  120. 120.
    Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11:701–713CrossRefGoogle Scholar
  121. 121.
    Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, Kavanaugh WM, Williams LT (1998) Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 18:5699–5711CrossRefGoogle Scholar
  122. 122.
    Koncar RF, Feldman R, Bahassi EM, Hashemi Sadraei N (2017) Comparative molecular profiling of HPV-induced squamous cell carcinomas. Cancer Med 6:1673–1685CrossRefGoogle Scholar
  123. 123.
    Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY (2000) PIK3CA as an oncogene in cervical cancer. Oncogene 19:2739–2744CrossRefGoogle Scholar
  124. 124.
    Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18:77–82CrossRefGoogle Scholar
  125. 125.
    Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA (2015) Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 26:1216–1223CrossRefGoogle Scholar
  126. 126.
    Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Trevino V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabino NB, Gomez-Macias GS, Valdez-Chapa LD, Garza-Rodriguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldana HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371–375CrossRefGoogle Scholar
  127. 127.
    Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Bragelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS (2015) Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21:632–641 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  128. 128.
    Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, O’Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C (2013) Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 5:49CrossRefGoogle Scholar
  129. 129.
    Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3:761–769CrossRefGoogle Scholar
  130. 130.
    Vogt PK, Kang S, Elsliger MA, Gymnopoulos M (2007) Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32:342–349CrossRefGoogle Scholar
  131. 131.
    Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627–644CrossRefGoogle Scholar
  132. 132.
    Cancer Genome Atlas Research, N., M. Albert Einstein College of, S. Analytical Biological, H. Barretos Cancer, M. Baylor College of, H. Beckman Research Institute of City of, A. Buck Institute for Research on, C. Canada’s Michael Smith Genome Sciences, S. Harvard Medical, F. G. C. C. Helen, S. Research Institute at Christiana Care Health, B. HudsonAlpha Institute for, L. L. C. Ilsbio, M. Indiana University School of, V. Institute of Human, B. Institute for Systems, C. International Genomics, B. Leidos, H. Massachusetts General, U. McDonnell Genome Institute at Washington, W. Medical College of, C. Medical University of South, C. Memorial Sloan Kettering Cancer, C. Montefiore Medical, NantOmics, I. National Cancer, A. N. National Hospital, I. National Human Genome Research, S. National Institute of Environmental Health, D. National Institute on, D. Other Communication, L. H. S. C. Ontario Tumour Bank, O. I. f. C. R. Ontario Tumour Bank, T. O. H. Ontario Tumour Bank, H. Oregon, U. Science, C.-S. M. C. Samuel Oschin Comprehensive Cancer Institute, S. R. A. International, S. St Joseph’s Candler Health, Eli, L. B. I. o. M. I. o. T. Edythe, U. Harvard, H. Research Institute at Nationwide Children’s, U. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, B. University of, M. D. A. C. C. University of Texas, H. University of Abuja Teaching, B. University of Alabama at, I. University of California, C. University of California Santa, C. University of Kansas Medical, L. University of, C. University of New Mexico Health Sciences, H. University of North Carolina at Chapel, C. University of Oklahoma Health Sciences, P. University of, R. a. P. M. S. University of Sao Paulo, C. University of Southern, W. University of, M. University of Wisconsin School of, H. Public, I. Van Andel Research, and L. Washington University in St (2017) Integrated genomic and molecular characterization of cervical cancer. Nature 543:378–384CrossRefGoogle Scholar
  133. 133.
    Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin KL (2009) Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol 34:409–416Google Scholar
  134. 134.
    Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juarez-Torres E, Medina-Martinez I, Roman-Basaure E, Mitchell J, Roberson D, Sawitzke J, Garland L, Rodriguez-Herrera M, Wells D, Troyer J, Pinto FC, Bass S, Zhang X, Castillo M, Gold B, Morales H, Yeager M, Berumen J, Alvirez E, Gharzouzi E, Dean M (2015) Genome analysis of latin American cervical cancer: frequent activation of the PIK3CA pathway. Clin Cancer Res 21:5360–5370 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  135. 135.
    McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM (2013) PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 128:409–414CrossRefGoogle Scholar
  136. 136.
    Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM (2014) TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 12:255CrossRefGoogle Scholar
  137. 137.
    Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS (2013) Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783CrossRefGoogle Scholar
  138. 138.
    Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, Teknos T (2016) Molecular profiling of head and neck squamous cell carcinoma. Head Neck 38(Suppl 1):E1625–E1638CrossRefGoogle Scholar
  139. 139.
    Stelzer MK, Pitot HC, Liem A, Lee D, Kennedy GD, Lambert PF (2010) Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) 3:1542–1551CrossRefGoogle Scholar
  140. 140.
    Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR (2015) Increased expression of HER2, HER3, and HER2:HER3 heterodimers in HPV-positive HNSCC using a novel proximity-based assay: implications for targeted therapies. Clinical Cancer Research 21:4597–4606 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  141. 141.
    Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR (2017) Human Papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. Clin Cancer Res 23:3072–3083 (An official journal of the American Association for Cancer Research)CrossRefGoogle Scholar
  142. 142.
    Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, Jr., de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE, Lux H, Investigators N (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16:583–594CrossRefGoogle Scholar
  143. 143.
    Lesseur C, Diergaarde B, Olshan AF, Wunsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsague X, Conway DI, Holcatova I, Mates D, Vilensky M, Healy CM, Szeszenia-Dabrowska N, Fabianova E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P (2016) Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet 48:1544–1550CrossRefGoogle Scholar
  144. 144.
    Chen D, Gyllensten U (2015) Lessons and implications from association studies and post-GWAS analyses of cervical cancer. Trends Genet 31:41–54CrossRefGoogle Scholar
  145. 145.
    Martinez-Nava GA, Fernandez-Nino JA, Madrid-Marina V, Torres-Poveda K (2016) Cervical cancer genetic susceptibility: a systematic review and meta-analyses of recent evidence. PLoS ONE 11:e0157344CrossRefGoogle Scholar
  146. 146.
    Hajek M, Sewell A, Kaech S, Burtness B, Yarbrough WG, Issaeva N (2017) TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma. Cancer 123:1778–1790CrossRefGoogle Scholar
  147. 147.
    Cameron JE, Mercante D, O’Brien M, Gaffga AM, Leigh JE, Fidel PL Jr, Hagensee ME (2005) The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis 32:703–709CrossRefGoogle Scholar
  148. 148.
    Coutlee F, Trottier AM, Ghattas G, Leduc R, Toma E, Sanche G, Rodrigues I, Turmel B, Allaire G, Ghadirian P (1997) Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis 24:23–31CrossRefGoogle Scholar
  149. 149.
    Fakhry C, D’Souza G, Sugar E, Weber K, Goshu E, Minkoff H, Wright R, Seaberg E, Gillison M (2006) Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44:4479–4485CrossRefGoogle Scholar
  150. 150.
    Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92:1500–1510CrossRefGoogle Scholar
  151. 151.
    Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420CrossRefGoogle Scholar
  152. 152.
    Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML (2004) Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189:686–698CrossRefGoogle Scholar
  153. 153.
    Beachler DC, Sugar EA, Margolick JB, Weber KM, Strickler HD, Wiley DJ, Cranston RD, Burk RD, Minkoff H, Reddy S, Xiao W, Guo Y, Gillison ML, D’Souza G (2015) Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol 181:40–53CrossRefGoogle Scholar
  154. 154.
    Mooij SH, van der Klis FR, van der Sande MA, Schepp RM, Speksnijder AG, Bogaards JA, de Melker HE, de Vries HJ, Snijders PJ, van der Loeff MF (2013) Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: the H2 M study. Cancer Epidemiol Biomark Prev 22:1698–1708 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)CrossRefGoogle Scholar
  155. 155.
    Parisi SG, Cruciani M, Scaggiante R, Boldrin C, Andreis S, Dal Bello F, Pagni S, Barelli A, Sattin A, Mengoli C, Palu G (2011) Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 11:150CrossRefGoogle Scholar
  156. 156.
    Read TR, Hocking JS, Vodstrcil LA, Tabrizi SN, McCullough MJ, Grulich AE, Garland SM, Bradshaw CS, Chen MY, Fairley CK (2012) Oral human papillomavirus in men having sex with men: risk-factors and sampling. PLoS ONE 7:e49324CrossRefGoogle Scholar
  157. 157.
    King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P (2016) Oral human papillomavirus infection in men who have sex with men: a systematic review and meta-analysis. PLoS ONE 11:e0157976CrossRefGoogle Scholar
  158. 158.
    Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101:1120–1130CrossRefGoogle Scholar
  159. 159.
    Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425–432CrossRefGoogle Scholar
  160. 160.
    Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL (2008) Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol 80:953–959CrossRefGoogle Scholar
  161. 161.
    Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA (2016) Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS 30:1573–1582CrossRefGoogle Scholar
  162. 162.
    Steinau M, Reddy D, Sumbry A, Reznik D, Gunthel CJ, Del Rio C, Lennox JL, Unger ER, Nguyen ML (2012) Oral sampling and human papillomavirus genotyping in HIV-infected patients. J. Oral Pathol Med 41:288–291 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)CrossRefGoogle Scholar
  163. 163.
    Sirera G, Videla S, Pinol M, Canadas MP, Llatjos M, Ballesteros AL, Garcia-Cuyas F, Castella E, Guerola R, Tural C, Rey-Joly C, Clotet B (2006) High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS 20:1201–1204CrossRefGoogle Scholar
  164. 164.
    Fatahzadeh M, Schlecht NF, Chen Z, Bottalico D, McKinney S, Ostoloza J, Dunne A, Burk RD (2013) Oral human papillomavirus detection in older adults who have human immunodeficiency virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol 115:505–514CrossRefGoogle Scholar
  165. 165.
    Blas MM, Brown B, Menacho L, Alva IE, Silva-Santisteban A, Carcamo C (2015) HPV prevalence in multiple anatomical sites among men who have sex with men in Peru. PLoS ONE 10:e0139524CrossRefGoogle Scholar
  166. 166.
    Videla S, Darwich L, Canadas MP, Coll J, Pinol M, Garcia-Cuyas F, Molina-Lopez RA, Cobarsi P, Clotet B, Sirera G (2013) Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 40:3–10CrossRefGoogle Scholar
  167. 167.
    van Rijn VM, Mooij SH, Mollers M, Snijders PJ, Speksnijder AG, King AJ, de Vries HJ, van Eeden A, van der Klis FR, de Melker HE, van der Sande MA, van der Loeff MF (2014) Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men. PLoS ONE 9:e92208CrossRefGoogle Scholar
  168. 168.
    Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606–2611CrossRefGoogle Scholar
  169. 169.
    Richter KL, van Rensburg EJ, van Heerden WF, Boy SC (2008) Human papilloma virus types in the oral and cervical mucosa of HIV-positive South African women prior to antiretroviral therapy. J Oral Pathol Med 37:555–559 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)CrossRefGoogle Scholar
  170. 170.
    Ong JJ, Read TR, Vodstrcil LA, Walker S, Chen M, Bradshaw CS, Garland SM, Tabrizi SN, Cornall A, Grulich A, Hocking J, Fairley CK (2014) Detection of oral human papillomavirus in HIV-positive men who have sex with men 3 years after baseline: a follow up cross-sectional study. PLoS ONE 9:e102138CrossRefGoogle Scholar
  171. 171.
    van Aar F, Mooij SH, van der Sande MA, Meijer CJ, King AJ, Verhagen DW, Heijman T, Coutinho RA, Schim van der Loeff MF (2014) Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study. BMC Infect Dis 14:668CrossRefGoogle Scholar
  172. 172.
    D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL, Anastos K, Palefsky JM, Gillison ML (2007) Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121:143–150CrossRefGoogle Scholar
  173. 173.
    Lam JO, Bream JH, Sugar EA, Coles CL, Weber KM, Burk RD, Wiley DJ, Cranston RD, Reddy S, Margolick JB, Strickler HD, Wentz A, Jacobson L, Guo Y, Xiao W, Gillison ML, D’Souza G (2016) Association of serum cytokines with oral HPV clearance. Cytokine 83:85–91CrossRefGoogle Scholar
  174. 174.
    Greenspan D, de Villiers EM, Greenspan JS, de Souza YG, zur Hausan H (1988) Unusual HPV types in oral warts in association with HIV infection. J Oral Pathol 17:482–488CrossRefGoogle Scholar
  175. 175.
    Anaya-Saavedra G, Flores-Moreno B, Garcia-Carranca A, Irigoyen-Camacho E, Guido-Jimenez M, Ramirez-Amador V (2013) HPV oral lesions in HIV-infected patients: the impact of long-term HAART. J Oral Pathol Med 42:443–449 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)CrossRefGoogle Scholar
  176. 176.
    Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, Lewis CW, Salasche SJ, Turner ML, Lowery BJ (1995) Guidelines of care for warts: human papillomavirus. Committee on Guidelines of Care. J Am Acad Dermatol 32:98–103CrossRefGoogle Scholar
  177. 177.
    Lozada-Nur F, Glick M, Schubert M, Silverberg I (2001) Use of intralesional interferon-alpha for the treatment of recalcitrant oral warts in patients with AIDS: a report of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:617–622CrossRefGoogle Scholar
  178. 178.
    DeRossi SS, Laudenbach J (2004) The management of oral human papillomavirus with topical cidofovir: a case report. Cutis 73:191–193Google Scholar
  179. 179.
    Mun JH, Kim SH, Jung DS, Ko HC, Kim BS, Kwon KS, Kim MB (2011) Oral zinc sulfate treatment for viral warts: an open-label study. J Dermatol 38:541–545CrossRefGoogle Scholar
  180. 180.
    Kaur GJ, Brar BK, Kumar S, Brar SK, Singh B (2017) Evaluation of the efficacy and safety of oral isotretinoin versus topical isotretinoin in the treatment of plane warts: a randomized open trial. Int J Dermatol 56:1352–1358CrossRefGoogle Scholar
  181. 181.
    Snietura M, Lamch R, Kopec A, Waniczek D, Likus W, Lange D, Markowski J (2017) Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection. Eur Arch Otorhinolaryngol 274:3477–3483CrossRefGoogle Scholar
  182. 182.
    Piattelli A, Rubini C, Fioroni M, Iezzi T (2001) Warty carcinoma of the oral mucosa in an HIV+ patient. Oral Oncol 37:665–667CrossRefGoogle Scholar
  183. 183.
    Dona MG, Pichi B, Rollo F, Gheit T, Laquintana V, Covello R, Pescarmona E, Spriano G, Pellini R, Giuliani M, Tommasino M, Benevolo M (2017) Mucosal and cutaneous human papillomaviruses in head and neck squamous cell papillomas. Head Neck 39:254–259CrossRefGoogle Scholar
  184. 184.
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612–619CrossRefGoogle Scholar
  185. 185.
    Gillison ML (2009) Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol 21:439–444CrossRefGoogle Scholar
  186. 186.
    D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956CrossRefGoogle Scholar
  187. 187.
    Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187–194CrossRefGoogle Scholar
  188. 188.
    Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67CrossRefGoogle Scholar
  189. 189.
    Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728–736CrossRefGoogle Scholar
  190. 190.
    Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52:611–622CrossRefGoogle Scholar
  191. 191.
    Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Burchell AN, Korthuis PT, Moore RD, D’Souza G (2014) Incidence and risk factors of HPV-related and HPV-unrelated head and neck squamous cell carcinoma in HIV-infected individuals. Oral Oncol 50:1169–1176CrossRefGoogle Scholar
  192. 192.
    Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U (2003) Therapeutic approaches to AIDS-related malignancies. Oncogene 22:6646–6659CrossRefGoogle Scholar
  193. 193.
    Simard EP, Pfeiffer RM, Engels EA (2010) Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 170:1337–1345CrossRefGoogle Scholar
  194. 194.
    Demopoulos BP, Vamvakas E, Ehrlich JE, Demopoulos R (2003) Non-acquired immunodeficiency syndrome-defining malignancies in patients infected with human immunodeficiency virus. Arch Pathol Lab Med 127:589–592Google Scholar
  195. 195.
    Chew EY, Hartman CM, Richardson PA, Zevallos JP, Sikora AG, Kramer JR, Chiao EY (2017) Risk factors for oropharynx cancer in a cohort of HIV-infected veterans. Oral Oncol 68:60–66CrossRefGoogle Scholar
  196. 196.
    Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Dubrow R, Quesenberry CP Jr, Neugebauer RS, Abrams DI (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomark Prev 20:2551–2559 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)CrossRefGoogle Scholar
  197. 197.
    Picard A, Badoual C, Hourseau M, Halimi C, Pere H, Dib F, Barry B, Albert S (2016) Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS 30:1257–1266CrossRefGoogle Scholar
  198. 198.
    McLemore MS, Haigentz M Jr, Smith RV, Nuovo GJ, Alos L, Cardesa A, Brandwein-Gensler M (2010) Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 4:97–105CrossRefGoogle Scholar
  199. 199.
    Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefGoogle Scholar
  200. 200.
    Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747 (Official journal of the American Society of Clinical Oncology)CrossRefGoogle Scholar
  201. 201.
    Kimple RJ, Harari PM (2014) Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol 50:560–564CrossRefGoogle Scholar
  202. 202.
    Singh B, Sabin S, Rofim O, Shaha A, Har-El G, Lucente FE (1999) Alterations in head and neck cancer occurring in HIV-infected patients–results of a pilot, longitudinal, prospective study. Acta Oncol 38:1047–1050CrossRefGoogle Scholar
  203. 203.
    D’Souza G, Carey TE, William WN Jr., Nguyen ML, Ko EC, Riddell JT, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65:603–610CrossRefGoogle Scholar
  204. 204.
    Grew DJ, Cooper BT, Nguy S, Halperin J, Sanfilippo NJ (2014) Toxicity and disease-related outcomes after radiotherapy for head and neck cancer in human immunodeficiency virus-positive patients. Front Oncol 4:316CrossRefGoogle Scholar
  205. 205.
    Mourad WF, Hu KS, Shasha D, Concert C, Ishihara D, Lin W, Gamez ME, Lukens JN, Shourbaji RA, Ryniak M, Li Z, Culliney BE, Khorsandi AS, Tran T, Jacobson A, Manolidis S, Schantz S, Urken M, Persky MS, Harrison LB (2013) Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer Res 33:5511–5516Google Scholar
  206. 206.
    Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjonneland A, Overvad K, Quiros JR, Gonzalez CA, Sanchez MJ, Larranaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, Ekstrom J, Skeie G, Lund E, Weiderpass E, Ferrari P, Byrnes G, Romieu I, Riboli E, Hildesheim A, Boeing H, Pawlita M, Brennan P (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31:2708–2715 (Official journal of the American Society of Clinical Oncology)CrossRefGoogle Scholar
  207. 207.
    Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS (2001) Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357:1411–1412CrossRefGoogle Scholar
  208. 208.
    Ortega KL, Vale DA, Magalhaes MH (2009) Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients. J Oral Pathol Med 38:489–494 (Official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology)CrossRefGoogle Scholar
  209. 209.
    Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr (2000) Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89:299–304CrossRefGoogle Scholar
  210. 210.
    Tappuni AR, Fleming GJ (2001) The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92:623–628CrossRefGoogle Scholar
  211. 211.
    Leigh J (2000) Oral warts rise dramatically with use of new agents in HIV. HIV Clin 12:7Google Scholar
  212. 212.
    King MD, Reznik DA, O’Daniels CM, Larsen NM, Osterholt D, Blumberg HM (2002) Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 34:641–648CrossRefGoogle Scholar
  213. 213.
    Batavia AS, Secours R, Espinosa P, Jean Juste MA, Severe P, Pape JW, Fitzgerald DW (2016) Diagnosis of HIV-associated oral lesions in relation to early versus delayed antiretroviral therapy: results from the CIPRA HT001 trial. PLoS ONE 11:e0150656CrossRefGoogle Scholar
  214. 214.
    Lilly EA, Cameron JE, Shetty KV, Leigh JE, Hager S, McNulty KM, Cheeks C, Hagensee ME, Fidel PL Jr (2005) Lack of evidence for local immune activity in oral hairy leukoplakia and oral wart lesions. Oral Microbiol Immunol 20:154–162CrossRefGoogle Scholar
  215. 215.
    Danaher RJ, Wang C, Roland AT, Kaetzel CS, Greenberg RN, Miller CS (2010) HIV protease inhibitors block oral epithelial cell DNA synthesis. Arch Oral Biol 55:95–100CrossRefGoogle Scholar
  216. 216.
    Badley AD (2005) In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ 12(Suppl 1):924–931CrossRefGoogle Scholar
  217. 217.
    Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? The Lancet. Oncology 10:61–71Google Scholar
  218. 218.
    Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA (2013) HPV-related cancers after solid organ transplantation in the United States. Am J Transplant 13:3202–3209 (Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons)CrossRefGoogle Scholar
  219. 219.
    Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H, Bower M (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884–890CrossRefGoogle Scholar
  220. 220.
    Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomin A, Bellu F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 100:840–847CrossRefGoogle Scholar
  221. 221.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651CrossRefGoogle Scholar
  222. 222.
    Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032CrossRefGoogle Scholar
  223. 223.
    Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D (2014) Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother. 10:2147–2162CrossRefGoogle Scholar
  224. 224.
    Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14:467–475 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)CrossRefGoogle Scholar
  225. 225.
    Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, Lynch CF, Wilkinson EJ, Hernandez BY, Copeland G, Saber MS, Hopenhayn C, Huang Y, Cozen W, Lyu C, Unger ER (2014) Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 20:822–828CrossRefGoogle Scholar
  226. 226.
    Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, Razzaghi H, Saraiya M (2016) Human Papillomavirus-associated cancers - United States, 2008–2012. MMWR Morb Mortal Wkly Rep 65:661–666CrossRefGoogle Scholar
  227. 227.
    Cameron JE, Snowhite IV, Chaturvedi AK, Hagensee ME (2003) Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol 10:431–438PubMedCentralGoogle Scholar
  228. 228.
    Marais DJ, Best JM, Rose RC, Keating P, Soeters R, Denny L, Dehaeck CM, Nevin J, Kay P, Passmore JA, Williamson AL (2001) Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol 65:149–154CrossRefGoogle Scholar
  229. 229.
    Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR (2016) Quadrivalent Human Papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial. J Infect Dis 214:1276–1283CrossRefGoogle Scholar
  230. 230.
    Rowhani-Rahbar A, Carter JJ, Hawes SE, Hughes JP, Weiss NS, Galloway DA, Koutsky LA (2009) Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 200:1452–1455CrossRefGoogle Scholar
  231. 231.
    Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR (2013) Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8:e68329CrossRefGoogle Scholar
  232. 232.
    Hirth JM, Chang M, Resto VA (2017) Prevalence of oral human papillomavirus by vaccination status among young adults (18–30 years old). Vaccine 35:3446–3451CrossRefGoogle Scholar
  233. 233.
    Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A (2010) Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 55:197–204CrossRefGoogle Scholar
  234. 234.
    Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM (2010) Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202:1246–1253CrossRefGoogle Scholar
  235. 235.
    Meites E, Kempe A, Markowitz LE (2016) Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 65:1405–1408CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Microbiology, Immunology and ParasitologyLouisiana State University Health Sciences CenterNew OrleansUSA
  2. 2.Department of MedicineSection of Infectious DiseasesNew OrleansUSA

Personalised recommendations